← Back

DexCom: DexCom's Strong Q2 Performance Driven by Revenue Growth and Margin Expansion

DexCom's second-quarter 2025 revenue grew 15% to $1.16 billion, with US revenue totaling $841 million and international revenue growing 16% to $316 million. The company's gross profit was $695.9 million or 60.1% of revenue, and operating income was $221.8 million or 19.2% of revenue. Adjusted EBITDA was $327.6 million or 28.3% of revenue. DexCom's cash and cash equivalents stood at approximately $2.9 billion. The company's EPS came out at $0.48, beating estimates of $0.4436. According to management, the guidance increase is due to a solid start in the non-insulin opportunity, particularly with the three major PBMs covering non-insulin users.

DXCM

USD 65.75

-0.93%

A-Score: 4.1/10

Publication date: July 30, 2025

Full Report

Author: Analystock.ai

📋 Highlights
  • Revenue Growth: 15% increase to $1.16 billion, with US revenue at $841 million and international up 16% to $316 million.
  • Gross Profit: $695.9 million, representing 60.1% of revenue, with operating income at $221.8 million (19.2% of revenue) and adjusted EBITDA at $327.6 million (28.3% of revenue).
  • Cash Position: $2.9 billion in cash and cash equivalents, indicating strong liquidity.
  • Guidance Increase: Raised full-year revenue guidance to $4.6-$4.625 billion, reflecting 14%-15% growth.
  • Leadership Transition: Kevin Sayer to step down, with Jake Leach taking over as CEO in 2026, signaling a strategic shift in leadership.

Financial Performance and Guidance

The company raised its revenue guidance to a range of $4.6 billion to $4.625 billion, representing growth of 14% to 15% for the year. This increase is driven by the strong performance of its core business and new product launches. DexCom's CEO, Kevin Sayer, stated that the company is excited about its next-generation wearable platform, G8, which is 50% smaller and has more functionality.

Operational Highlights and New Product Launches

DexCom reported notable achievements in its core business and new product launches, including over 400,000 app downloads for Stelo, a non-invasive glucose monitoring system. The company is working on a randomized controlled trial to study the effectiveness of continuous glucose monitoring (CGM) in type2 non-insulin users. Additionally, DexCom has several registries to collect real-world evidence on the effectiveness of CGM in this population.

Competitive Dynamics and Market Outlook

On competitive dynamics, Leach noted that while there is discussion around dual-analyte sensors, DexCom's focus is on features that extend safety and ease of use. The company is working on a ketone sensor but will launch it when appropriate. Regarding the CMS competitive bidding for CGM and pumps, DexCom estimates that about 15% of its business is fee-for-service Medicare.

Valuation and Analyst Estimates

DexCom's valuation metrics suggest that the stock may be trading at a premium. The company's P/E Ratio is 55.42, P/B Ratio is 12.31, and P/S Ratio is 7.36. The EV/EBITDA ratio is 35.03, and the Dividend Yield is 0.0%. Analysts estimate next year's revenue growth at 15.5%, which is in line with the company's guidance.

Succession Plan and Leadership Transition

DexCom announced its succession plan, with Kevin Sayer handing over CEO responsibilities to Jake Leach at the beginning of 2026. The company's leadership transition is expected to be smooth, with Leach outlining his vision for DexCom, focusing on driving innovation, expanding access to CGM technology globally, and building operational scale.

DexCom's A-Score